JP2004537550A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537550A5
JP2004537550A5 JP2003513558A JP2003513558A JP2004537550A5 JP 2004537550 A5 JP2004537550 A5 JP 2004537550A5 JP 2003513558 A JP2003513558 A JP 2003513558A JP 2003513558 A JP2003513558 A JP 2003513558A JP 2004537550 A5 JP2004537550 A5 JP 2004537550A5
Authority
JP
Japan
Prior art keywords
group
salt
structural formula
acid
pharmaceutically suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003513558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4598390B2 (ja
JP2004537550A (ja
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed filed Critical
Priority claimed from PCT/HU2002/000067 external-priority patent/WO2003007951A1/en
Publication of JP2004537550A publication Critical patent/JP2004537550A/ja
Publication of JP2004537550A5 publication Critical patent/JP2004537550A5/ja
Application granted granted Critical
Publication of JP4598390B2 publication Critical patent/JP4598390B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003513558A 2001-07-17 2002-07-10 糖尿病予防、または糖尿病治療のための相乗作用の薬学的組成物 Expired - Fee Related JP4598390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2004537550A JP2004537550A (ja) 2004-12-16
JP2004537550A5 true JP2004537550A5 (https=) 2009-06-18
JP4598390B2 JP4598390B2 (ja) 2010-12-15

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003513558A Expired - Fee Related JP4598390B2 (ja) 2001-07-17 2002-07-10 糖尿病予防、または糖尿病治療のための相乗作用の薬学的組成物

Country Status (21)

Country Link
US (2) US7635674B2 (https=)
EP (1) EP1408966B1 (https=)
JP (1) JP4598390B2 (https=)
KR (1) KR100920560B1 (https=)
CN (1) CN1270713C (https=)
AT (1) ATE386523T1 (https=)
AU (1) AU2002354884B2 (https=)
BR (1) BR0210744A (https=)
CA (2) CA2452558C (https=)
CY (1) CY1107939T1 (https=)
DE (1) DE60225143T2 (https=)
DK (1) DK1408966T3 (https=)
ES (1) ES2300460T3 (https=)
IL (2) IL159412A0 (https=)
MX (1) MXPA04000324A (https=)
NO (1) NO20040153L (https=)
NZ (1) NZ531155A (https=)
PL (1) PL205826B1 (https=)
PT (1) PT1408966E (https=)
RU (1) RU2311907C2 (https=)
WO (1) WO2003007951A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2357983T3 (es) * 2006-11-02 2011-05-04 N-Gene Research Laboratories Inc. Composición farmacéutica que presenta una actividad antipsicótica, antidepresiva o antiepiléptica con un efecto secundario reducido.
ZA200902760B (en) * 2006-11-02 2010-06-30 N-Gene Res Lab Inc Reduction of overweight or obesity
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
EA020870B1 (ru) 2007-07-19 2015-02-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
ES2638977T3 (es) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
CN103547588B (zh) 2011-04-13 2016-06-29 Isis制药公司 Ptp1b表达的反义调节
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
CA3067746A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
JP7536119B2 (ja) * 2020-05-27 2024-08-19 コーセプト セラピューティクス, インコーポレイテッド グルココルチコイド受容体モジュレーターレラコリラントおよびcyp2c9基質の併用投与
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Similar Documents

Publication Publication Date Title
US8048873B2 (en) Synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP2004537550A5 (https=)
AU2005299808B2 (en) Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
US20060111428A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
KR100506428B1 (ko) 대사 장애, 특히 당뇨병 또는 당뇨병 관련 질환 또는증상의 치료 방법
EP1248604A2 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP2006523668A (ja) 糖尿病の予防又は治療のためのシクレタニンを含有する相乗作用の薬学的組合せ
US20140142145A1 (en) Combinations comprising a dipeptidylpeptidase - iv inhibitor
US20100056460A1 (en) Combination of organic compounds
CN1840195A (zh) 一种用于预防或治疗糖尿病的协同药物组合物
HUP0400762A2 (hu) Gyógyászati készítmény a diabetesz megelőzésére vagy kezelésére
JP4588448B2 (ja) PPARγアゴニストによる治療に伴う体重増加を治療するためのPPARαアゴニストの使用